Zoom Beats Earnings Estimates; Palantir and Kinsale Capital Show Strong Guidance
- Zoom's Strong Earnings: Zoom reported third-quarter revenue of $1.23 billion on November 24, surpassing the consensus estimate of $1.21 billion, indicating robust cash flow and market demand that could drive stock price growth.
- Palantir's Positive Outlook: Palantir's fourth-quarter results exceeded expectations, and the company provided first-quarter sales guidance above estimates, along with FY26 guidance that also surpassed analyst forecasts, highlighting its future growth potential.
- Kinsale Capital's Optimistic Forecast: Kinsale Capital shares rose 0.4% to close at $410.44 on Thursday, with analyst Hristian Getsov initiating coverage with an Overweight rating and a $490 price target, reflecting market confidence in its future performance.
- Merck's Drug Approval: Merck's ENFLONSIA received approval from Health Canada for preventing RSV lower respiratory tract disease in newborns and infants, with shares gaining 1.2% to close at $119.75, showcasing the company's ongoing innovation in the healthcare sector.
Trade with 70% Backtested Accuracy
Analyst Views on KNSL
About KNSL
About the author
Zoom Beats Earnings Estimates; Palantir and Kinsale Capital Show Strong Guidance
- Zoom's Strong Earnings: Zoom reported third-quarter revenue of $1.23 billion on November 24, surpassing the consensus estimate of $1.21 billion, indicating robust cash flow and market demand that could drive stock price growth.
- Palantir's Positive Outlook: Palantir's fourth-quarter results exceeded expectations, and the company provided first-quarter sales guidance above estimates, along with FY26 guidance that also surpassed analyst forecasts, highlighting its future growth potential.
- Kinsale Capital's Optimistic Forecast: Kinsale Capital shares rose 0.4% to close at $410.44 on Thursday, with analyst Hristian Getsov initiating coverage with an Overweight rating and a $490 price target, reflecting market confidence in its future performance.
- Merck's Drug Approval: Merck's ENFLONSIA received approval from Health Canada for preventing RSV lower respiratory tract disease in newborns and infants, with shares gaining 1.2% to close at $119.75, showcasing the company's ongoing innovation in the healthcare sector.
Jacobson & Schmitt Advisors Buys 6,661 Kinsale Capital Shares for $2.72 Million
- Share Increase: Jacobson & Schmitt Advisors reported a purchase of 6,661 shares of Kinsale Capital Group in a January 20 SEC filing, with an estimated transaction value of $2.72 million, reflecting confidence in the company.
- Asset Management Status: Following the purchase, Kinsale Capital accounted for 2.82% of the fund's reportable AUM in the 13F report, indicating its significance within the investment portfolio.
- Financial Performance: Kinsale Capital's latest quarter saw net income rise to $141.6 million, or $6.09 per diluted share, marking a 24% year-over-year increase, demonstrating its ability to maintain profitability in a competitive market.
- Stock Buyback: The company repurchased $20 million worth of shares over the past year, and despite underperforming stock prices, its ongoing capital generation and shareholder return strategy highlight its long-term investment value.
RBC Initiates Coverage on Nvidia with $240 Price Target
- Nvidia's Positive Outlook: RBC initiates coverage on Nvidia with a price target of $240, citing a backlog exceeding $500 billion and surging enterprise AI demand as key drivers for stock upside, indicating strong market potential.
- Amazon Price Target Cut: Raymond James lowers Amazon's price target from $275 to $260, yet remains optimistic heading into Q4, believing robust holiday trends and advertising performance will support earnings, with the AI narrative likely influencing stock performance.
- Cautious Netflix Outlook: Wedbush reduces Netflix's price target from $140 to $115 due to disappointing Q3 results and Q4 guidance, reflecting market concerns about its future growth trajectory.
- Boeing Price Target Increase: Bernstein raises Boeing's price target from $277 to $298, expressing increasing confidence in the company's growth path for 2026, highlighting its strong position in the aerospace and defense sector.
Portfolio Analysis: Overview of Top Five Stock Investments
- Portfolio Overview: I own about 45 stocks in my portfolio, with some making up a significantly higher portion of my assets, indicating my confidence in specific companies and a long-term investment strategy.
- Market Dynamics: As of the morning prices on January 9, 2026, stock prices reflect market volatility and investor sentiment, influencing my investment decisions and portfolio adjustments.
- Investment Rationale: In the video, I provide brief comments on my largest investments, highlighting my views on each company and their future growth potential, aiming to help viewers understand my investment logic.
- Video Release: The video was published on January 10, 2026, intended to share my investment thoughts and strategies with viewers, fostering discussion on personal portfolio management.
Anthropic's IPO Might Arrive Sooner Than Expected!
Anthropic's IPO Plans: Anthropic, a competitor to OpenAI, is preparing for a potential IPO in 2026, aiming for a valuation that could place it among the largest IPOs in history, driven by significant private market interest and ambitious revenue projections.
AI Market Competition: The podcast discusses the competitive landscape of AI companies, highlighting the rapid advancements and spending in the sector, with Anthropic and OpenAI both facing pressure to innovate and secure funding amidst high valuations.
Klarna's Membership Program: Klarna is expanding its buy now, pay later services by introducing a membership program in the U.S. that offers perks similar to credit cards, aiming to attract higher-income consumers who prefer 0% interest payment options.
Investment Insights: Contributors share their investment perspectives, with a focus on companies like Alphabet and Klarna, emphasizing the evolving nature of the buy now, pay later market and the potential for growth in AI and semiconductor technologies.
Upcoming Ex-Dividend Dates for Baxter International, Kinsale Capital Group, and Bank of Hawaii
Upcoming Ex-Dividend Dates: Baxter International Inc, Kinsale Capital Group Inc, and Bank of Hawaii Corp will trade ex-dividend on 11/28/25, with respective dividends of $0.01, $0.17, and $0.70 scheduled for payment in January and December 2025.
Expected Price Adjustments: Following the ex-dividend date, shares of Baxter International Inc, Kinsale Capital Group Inc, and Bank of Hawaii Corp are expected to open lower by approximately 0.05%, 0.04%, and 1.05%, respectively.
Dividend Yield Estimates: The estimated annualized dividend yields for these companies are 0.21% for Baxter International Inc, 0.18% for Kinsale Capital Group Inc, and 4.19% for Bank of Hawaii Corp, indicating varying levels of return for investors.
Recent Stock Performance: On the day of reporting, shares of Baxter International Inc and Bank of Hawaii Corp are up about 2.6%, while Kinsale Capital Group Inc shares have increased by approximately 1.9%.
Zoom Beats Earnings Estimates; Palantir and Kinsale Capital Show Strong Guidance
- Zoom's Strong Earnings: Zoom reported third-quarter revenue of $1.23 billion on November 24, surpassing the consensus estimate of $1.21 billion, indicating robust cash flow and market demand that could drive stock price growth.
- Palantir's Positive Outlook: Palantir's fourth-quarter results exceeded expectations, and the company provided first-quarter sales guidance above estimates, along with FY26 guidance that also surpassed analyst forecasts, highlighting its future growth potential.
- Kinsale Capital's Optimistic Forecast: Kinsale Capital shares rose 0.4% to close at $410.44 on Thursday, with analyst Hristian Getsov initiating coverage with an Overweight rating and a $490 price target, reflecting market confidence in its future performance.
- Merck's Drug Approval: Merck's ENFLONSIA received approval from Health Canada for preventing RSV lower respiratory tract disease in newborns and infants, with shares gaining 1.2% to close at $119.75, showcasing the company's ongoing innovation in the healthcare sector.
Jacobson & Schmitt Advisors Buys 6,661 Kinsale Capital Shares for $2.72 Million
- Share Increase: Jacobson & Schmitt Advisors reported a purchase of 6,661 shares of Kinsale Capital Group in a January 20 SEC filing, with an estimated transaction value of $2.72 million, reflecting confidence in the company.
- Asset Management Status: Following the purchase, Kinsale Capital accounted for 2.82% of the fund's reportable AUM in the 13F report, indicating its significance within the investment portfolio.
- Financial Performance: Kinsale Capital's latest quarter saw net income rise to $141.6 million, or $6.09 per diluted share, marking a 24% year-over-year increase, demonstrating its ability to maintain profitability in a competitive market.
- Stock Buyback: The company repurchased $20 million worth of shares over the past year, and despite underperforming stock prices, its ongoing capital generation and shareholder return strategy highlight its long-term investment value.
RBC Initiates Coverage on Nvidia with $240 Price Target
- Nvidia's Positive Outlook: RBC initiates coverage on Nvidia with a price target of $240, citing a backlog exceeding $500 billion and surging enterprise AI demand as key drivers for stock upside, indicating strong market potential.
- Amazon Price Target Cut: Raymond James lowers Amazon's price target from $275 to $260, yet remains optimistic heading into Q4, believing robust holiday trends and advertising performance will support earnings, with the AI narrative likely influencing stock performance.
- Cautious Netflix Outlook: Wedbush reduces Netflix's price target from $140 to $115 due to disappointing Q3 results and Q4 guidance, reflecting market concerns about its future growth trajectory.
- Boeing Price Target Increase: Bernstein raises Boeing's price target from $277 to $298, expressing increasing confidence in the company's growth path for 2026, highlighting its strong position in the aerospace and defense sector.
Portfolio Analysis: Overview of Top Five Stock Investments
- Portfolio Overview: I own about 45 stocks in my portfolio, with some making up a significantly higher portion of my assets, indicating my confidence in specific companies and a long-term investment strategy.
- Market Dynamics: As of the morning prices on January 9, 2026, stock prices reflect market volatility and investor sentiment, influencing my investment decisions and portfolio adjustments.
- Investment Rationale: In the video, I provide brief comments on my largest investments, highlighting my views on each company and their future growth potential, aiming to help viewers understand my investment logic.
- Video Release: The video was published on January 10, 2026, intended to share my investment thoughts and strategies with viewers, fostering discussion on personal portfolio management.
Anthropic's IPO Might Arrive Sooner Than Expected!
Anthropic's IPO Plans: Anthropic, a competitor to OpenAI, is preparing for a potential IPO in 2026, aiming for a valuation that could place it among the largest IPOs in history, driven by significant private market interest and ambitious revenue projections.
AI Market Competition: The podcast discusses the competitive landscape of AI companies, highlighting the rapid advancements and spending in the sector, with Anthropic and OpenAI both facing pressure to innovate and secure funding amidst high valuations.
Klarna's Membership Program: Klarna is expanding its buy now, pay later services by introducing a membership program in the U.S. that offers perks similar to credit cards, aiming to attract higher-income consumers who prefer 0% interest payment options.
Investment Insights: Contributors share their investment perspectives, with a focus on companies like Alphabet and Klarna, emphasizing the evolving nature of the buy now, pay later market and the potential for growth in AI and semiconductor technologies.
Upcoming Ex-Dividend Dates for Baxter International, Kinsale Capital Group, and Bank of Hawaii
Upcoming Ex-Dividend Dates: Baxter International Inc, Kinsale Capital Group Inc, and Bank of Hawaii Corp will trade ex-dividend on 11/28/25, with respective dividends of $0.01, $0.17, and $0.70 scheduled for payment in January and December 2025.
Expected Price Adjustments: Following the ex-dividend date, shares of Baxter International Inc, Kinsale Capital Group Inc, and Bank of Hawaii Corp are expected to open lower by approximately 0.05%, 0.04%, and 1.05%, respectively.
Dividend Yield Estimates: The estimated annualized dividend yields for these companies are 0.21% for Baxter International Inc, 0.18% for Kinsale Capital Group Inc, and 4.19% for Bank of Hawaii Corp, indicating varying levels of return for investors.
Recent Stock Performance: On the day of reporting, shares of Baxter International Inc and Bank of Hawaii Corp are up about 2.6%, while Kinsale Capital Group Inc shares have increased by approximately 1.9%.
